Some of the views expressed in the following
notes on newly approved products should be
regarded as preliminary, as there may have been
limited published data at the time of
publication, and little experience in Australia
of their safety or efficacy. However, the
Editorial Executive Committee believes that
comments made in good faith at an early stage
may still be of value. Before new drugs are
prescribed, the Committee believes it is
important that more detailed information is
obtained from the manufacturer's approved
product information, a drug information centre
or some other appropriate source.
Zyclir (AMRAD Pharmaceuticals)
200 mg and
800 mg tablets and 250 mg intravenous
infusion
